1-4 of 4
Charles E. Prussak
Close
Sort by
Journal Articles

Development and Testing of a Glycoengineered Anti-ROR1 Antibody with Enhanced Capacity for Directing Antibody-Dependent Cellular Cytotoxicity (ADCC) of Chronic Lymphocytic Leukemia Cells

Md Kamrul Hasan, George Widhopf II, Christopher Oh, Christina Girgis, Charles E. Prussak, James B. Breitmeyer, Thomas J. Kipps
Journal: Blood
Blood (2023) 142 (Supplement 1): 6836.
https://doi.org/10.1182/blood-2023-187559
Published: 2023
Journal Articles

Durable and Specific Inhibition of ROR1 Signaling Associates with Prolonged Progression Free Survival in Patients with Chronic Lymphocytic Leukemia Treated with Cirmtuzumab

Michael Choi, MD, George F. Widhopf II, PhD, Jian Yu, PhD, Liguang Chen, PhD, Md. Kamrul Hasan, PhD, Laura Z. Rassenti, PhD, Emily Pittman, PhD, Karen Messer, PhD, Charlene Gutierrez, BS, Reilly Lilianna Kidwell, BSc, Charles E. Prussak, PharmD, PhD, Januario E Castro, MD, Catriona Jamieson, MD PhD, Thomas J. Kipps, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 829.
https://doi.org/10.1182/blood.V130.Suppl_1.829.829
Published: 2017
Journal Articles

Cirmtuzumab Vedotin (UC-961ADC3), An Anti-ROR1-Monomethyl Auristatin E Antibody-Drug Conjugate, Is a Potential Treatment For ROR1-Positive Leukemia and Solid Tumors

Bing Cui, Ph.D, George F. Widhopf, II, PhD, Charles E. Prussak, Ph.D., Christina C.N. Wu, PhD, Anil Sadarangani, PhD, Suping Zhang, PhD, Fitzgerald Lao, Catriona HM Jamieson, MD, PhD, Dennis A. Carson, M.D, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1637.
https://doi.org/10.1182/blood.V122.21.1637.1637
Published: 2013
Journal Articles

CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia

Clinical Trials & Observations
William G. Wierda, Mark J. Cantwell, Sandra J. Woods, Laura Z. Rassenti, Charles E. Prussak, Thomas J. Kipps
Journal: Blood
Blood (2000) 96 (9): 2917–2924.
https://doi.org/10.1182/blood.V96.9.2917
Published: 2000